MESOBLAST LIMITED (ASX:MSB) - MSB Trading - 2020, 44400259, page-7179 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum

Originally posted by dave sss: ↑
https://clinicaltrials.gov/ct2/show/NCT04371393?term=Stem+cells&cond=COVID&draw=2&rank=24

MSCs inCOVID-19 ARDS
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.Know the risks and potential benefitsof clinical studies and talk to your health care provider before participating. Read ourdisclaimerfor details.
ClinicalTrials.gov Identifier: NCT04371393
1
Recruitment Status: Not yet recruiting
First Posted: May 1, 2020
Last Update Posted: May 1, 2020
SeeContacts and Locations
Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborator:
Mesoblast, Inc.
Information provided by (Responsible Party):
Annetine Gelijns, Icahn School of Medicine at Mount Sinai

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record
Study Description

Go to
Brief Summary:
The mortality rate in SARS-CoV-2-related severe ARDS is high despite treatment with antivirals, glucocorticoids, immunoglobulins, and ventilation. Preclinical and clinical evidence indicate that MSCs migrate to the lung and respond to the pro-inflammatory lung environment by releasing anti-inflammatory factors reducing the proliferation of pro-inflammatory cytokines while modulating regulatory Tcellsand macrophages to promote resolution of inflammation. Therefore, MSCs may have the potential to increase survival in management of COVID-19 induced ARDS.
The primary objective of this phase 3 trial is to evaluate the efficacy and safety of the addition of the mesenchymal stromalcell(MSC) remestemcel-L® plus standard of care compared to placebo plus standard of care in patients with acute respiratory distress syndrome (ARDS) due to SARS-CoV-2. The secondary objective is to assess the impact of MSCs on inflammatory biomarkers.

Condition or disease Intervention/treatment Phase
1 Mesenchymal StromalCellsRemestemcel-L Biological: Remestemcel-L®Drug: Placebo Phase 3

Detailed Description:
This will be a randomized (1:1 ratio), double blind, parallel design, placebo controlled trial. Randomization will be stratified by clinical center and by moderate versus severe ARDS. The study is designed to have three interim analyses for stopping accrual early for efficacy and futility when 30%, 45% and 60% of the 300 patients have reached the primary endpoint using Bayesian predictive probabilities.
Patients will be randomized in a 1:1 allocation to intravenous infusion of MSCs (remestemcel-L®) plus standard of care versus placebo plus standard of care for the treatment of COVID-19 related ARDS:
Group 1: 2x10^6 MSC/kg of body weight plus standard of care, administered twice during the first week, with the second infusion at 4 days following the first infusion (± 1 day)
Group 2: Placebo (Plasma-Lyte) plus standard of care, administered twice during the first week, with the second infusion at 4 days following the first infusion (± 1 day) (control)
MSCs and placebo will initially be administered intravenously in the dose defined above at randomization. The rate of infusion may be tailored to the patient's respiratory status and fluid status, but the duration of infusion should not exceed 60 minutes.
Patients will be followed for 90 days post randomization, with assessment of pulmonary symptoms at 6 and 12 months.
Study Design

Go to

Study Type: Interventional (Clinical Trial)
1 EstimatedEnrollment: 300 participants
2 Allocation: Randomized
3 Intervention Model: Parallel Assignment
4 Intervention Model Description: This will be a randomized (1:1 ratio), double blind, parallel design, placebo controlled trial.
5 Masking: Triple (Participant, Investigator, Outcomes Assessor)
6 Masking Description: This is a randomized clinical trial, in which the patients and investigators are masked to treatment assignment.
7 Primary Purpose: Treatment
8 Official Title: MesenchymalStem Cellsfor the Treatment of Moderate to SevereCOVID-19 Acute Respiratory Distress Syndrome
9 EstimatedStudy Start Date: April 2020
10 EstimatedPrimary Completion Date: April 2021
11 EstimatedStudy Completion Date: April 2022

Resource links provided by the National Library of Medicine

Genetic and Rare Diseases Information Centerresources:Respiratory Distress Syndrome, Infant Acute Respiratory Distress Syndrome
U.S. FDA Resources
Arms and Interventions

Go to

Arm Intervention/treatment
1 Experimental: Remestemcel-L® Plus Standard of Care
Intravenous infusion of remestemcel-L® 2x10^6 MSC/kg of body weight plus standard of care
Biological: Remestemcel-L®
administered twice during the first week, with the second infusion at 4 days following the first injection (± 1 day)
2 Placebo Comparator: Placebo Plus Standard of Care
Placebo (Plasma-Lyte) plus standard of care
Drug: Placebo
administered twice during the first week, with second infusion at 4 days following the first injection (± 1 day)

Outcome Measures

Go to

Primary Outcome Measures:
Number of all-cause mortality [ Time Frame: 30 days ]
Number of all-cause mortality within 30 days of randomization.

Secondary Outcome Measures:
Number of days alive off mechanical ventilatory support [ Time Frame: 60 days ]
Number of days alive off mechanical ventilatory support calculated as the number of days, within the 60 days window, that patients were alive and free of mechanical ventilatory support.
Number of adverse events [ Time Frame: 30 days ]
Safety analyses will be assessed by adverse event rates calculated as the ratio of the total number of events over 30 days divided by total patient-time at risk for the specific event from randomization.
Number of participants alive at day 7 [ Time Frame: 7 days ]
Number of participants alive at day 14 [ Time Frame: 14 days ]
Number of participants alive at day 60 [ Time Frame: 60 days ]
Number of participants alive at day 90 [ Time Frame: 90 days ]
Number of participants with resolution and/or improvement of ARDS [ Time Frame: 7 days ]
The number and percent of patients with resolution and/or improvement of ARDS at day 7
Number of participants with resolution and/or improvement of ARDS [ Time Frame: 14 days ]
The number and percent of patients with resolution and/or improvement of ARDS at day 14
Number of participants with resolution and/or improvement of ARDS [ Time Frame: 21 days ]
The number and percent of patients with resolution and/or improvement of ARDS at day 21
Number of participants with resolution and/or improvement of ARDS [ Time Frame: 30 days ]
The number and percent of patients with resolution and/or improvement of ARDS at day 30
Change from baseline of the severity of ARDS [ Time Frame: baseline and 7 days ]
Change from baseline of the severity of ARDS according to Berlin Criteria at days 7 post-randomization Change from baseline of the severity of ARDS according to Berlin Criteria at days 7, 14, 21 and 30 post-randomization will be compared between treatment groups using a Cochran-Mantel-Haenszel test stratified by baseline severity.
Change from baseline of the severity of ARDS [ Time Frame: baseline and 14 days ]
Change from baseline of the severity of ARDS according to Berlin Criteria at days 14 post-randomization Change from baseline of the severity of ARDS according to Berlin Criteria at days 7, 14, 21 and 30 post-randomization will be compared between treatment groups using a Cochran-Mantel-Haenszel test stratified by baseline severity.
Change from baseline of the severity of ARDS [ Time Frame: baseline and 21 days ]
Change from baseline of the severity of ARDS according to Berlin Criteria at days 21 post-randomization Change from baseline of the severity of ARDS according to Berlin Criteria at days 7, 14, 21 and 30 post-randomization will be compared between treatment groups using a Cochran-Mantel-Haenszel test stratified by baseline severity.
Change from baseline of the severity of ARDS [ Time Frame: baseline and 30 days ]
Change from baseline of the severity of ARDS according to Berlin Criteria at days 30 post-randomization Change from baseline of the severity of ARDS according to Berlin Criteria at days 7, 14, 21 and 30 post-randomization will be compared between treatment groups using a Cochran-Mantel-Haenszel test stratified by baseline severity.
Length of stay [ Time Frame: 12 months ]
Hospital length of stay
Clinical Improvement Scale [ Time Frame: 7 days ]
Change from baseline in Clinical Improvement Scale at day 7. Clinical Improvement Scale full scale from 1 to 7, with higher score indicating more clinical improvement.
Clinical Improvement Scale [ Time Frame: 14 days ]
Change from baseline in Clinical Improvement Scale at day 14. Full scale from 1 to 7, with higher score indicating more clinical improvement.
Clinical Improvement Scale [ Time Frame: 21 days ]
Change from baseline in Clinical Improvement Scale at day 21. Clinical Improvement Scale full scale from 1 to y, with higher score indicating more clinical improvement.
Clinical Improvement Scale [ Time Frame: 30 days ]
Change from baseline in Clinical Improvement Scale at day 30. Clinical Improvement Scale full scale from 1 to 7, with higher score indicating more clinical improvement.
Change in serum hs-CRP concentration [ Time Frame: baseline and 7 days ]
Changes from baseline in serum hs-CRP concentration at days 7
Change in serum hs-CRP concentration [ Time Frame: baseline and 14 days ]
Changes from baseline in serum hs-CRP concentration at days 14
Change in serum hs-CRP concentration [ Time Frame: baseline and 21 days ]
Changes from baseline in serum hs-CRP concentration at days 21
Change in serum hs-CRP concentration [ Time Frame: baseline and 30 days ]
Changes from baseline in serum hs-CRP concentration at days 30
Change in IL-6 inflammatory marker level [ Time Frame: baseline and 7 days ]
Changes from baseline in IL-6 inflammatory marker level at 7 days
Change in IL-6 inflammatory marker level [ Time Frame: baseline and 14 days ]
Changes from baseline in IL-6 inflammatory marker level at 14 days
Change in IL-6 inflammatory marker level [ Time Frame: baseline and 21 days ]
Changes from baseline in IL-6 inflammatory marker level at 21 days
Change in IL-6 inflammatory marker level [ Time Frame: baseline and 30 days ]
Changes from baseline in IL-6 inflammatory marker level at 30 days
Change in IL-8 inflammatory marker level [ Time Frame: baseline and 7 days ]
Changes from baseline in IL-6 inflammatory marker level at 7 days
Change in IL-8 inflammatory marker level [ Time Frame: baseline and 14 days ]
Changes from baseline in IL-6 inflammatory marker level at 14 days
Change in IL-8 inflammatory marker level [ Time Frame: baseline and 21 days ]
Changes from baseline in IL-6 inflammatory marker level at 21 days
Change in IL-8 inflammatory marker level [ Time Frame: baseline and 30 days ]
Changes from baseline in IL-6 inflammatory marker level at 30 days
Change in TNF-alpha inflammatory marker level [ Time Frame: baseline and 7 days ]
Changes from baseline in TNF-alpha inflammatory marker level at 7 days
Change in TNF-alpha inflammatory marker level [ Time Frame: baseline and 14 days ]
Changes from baseline in TNF-alpha inflammatory marker level at 14 days
Change in TNF-alpha inflammatory marker level [ Time Frame: baseline and 21 days ]
Changes from baseline in TNF-alpha inflammatory marker level at 21 days
Change in TNF-alpha inflammatory marker level [ Time Frame: baseline and 30 days ]
Changes from baseline in TNF-alpha inflammatory marker level at 30 days
Eligibility Criteria

Go to

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information,Learn About Clinical Studies.

Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
1 Sexes Eligible for Study: All
2 Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria
18 years or older
Patient has coronavirus disease COVID-19 confirmed by real-time reverse transcription polymerase chain reaction (RT-PCR) assay or other diagnostic test
Patient requiring mechanical ventilatory support with moderate to severe ARDS as determined by the following criteria (adapted from the Berlin criteria)
Bilateral opacities must be present on a chest radiograph or computed tomographic (CT) scan. These opacities are not fully explained by pleural effusions, lobar collapse, lung collapse, or pulmonary nodules.
Respiratory failure not fully explained by cardiac failure or fluid overload.
Moderate to severe impairment of oxygenation must be present, as defined by the ratio of arterial oxygen tension to fraction of inspired oxygen (PaO2/FiO2). The severity of the hypoxemia defines the severity of the ARDS:
Moderate ARDS: PaO2/FiO2 >100 mmHg and ≤200 mmHg, on ventilator settings that include PEEP ≥5 cm H2O OR
Severe ARDS: PaO2/FiO2 ≤100 mmHg on ventilator settings that include PEEP ≥5 cm H2O
High sensitivity C-Reactive Protein (hs-CRP) serum level >4.0 mg/dL
Acute Physiologic and Chronic Health Evaluation (APACHE IV) score >5
The patient or his/her legally authorized representative (LAR) is able to provide informed consent
Exclusion Criteria
Currently receiving extracorporeal membrane oxygenation (ECMO) or high frequency oscillatory ventilation (HFOV)
Females who are pregnant or lactating
Patients with established positive bacterial blood cultures prior to enrollment or suspicion of superimposed bacterial pneumonia
Patients with untreated HIV infection
Patients who have been intubated for more than 72 hours
Creatinine clearance less than 30 mL/minute
LFTs (ALT or AST) > 5x normal
Known hypersensitivity to DMSO or to porcine or bovine proteins
History of prior respiratory disease with requirement for supplemental oxygen
Any end-stage organ disease which in the opinion of the investigator may possibly affect the safety of remestemcel-L treatment
Receiving an investigational cellular therapy agent
Contacts and Locations

Go to

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number):NCT04371393

Contacts
Contact: Mary Beth Marks (212) 659-9699 [email protected]

Sponsors and Collaborators
Icahn School of Medicine at Mount Sinai
Mesoblast, Inc.
Investigators
Principal Investigator: Annetine C Gelijns, PhD Icahn School of Medicine at Mount Sinai
1 Study Director: Michael Mack, MD Baylor Research Institute
2 Study Director: Peter Smith, MD Duke University
More Information

Go to

Responsible Party: Annetine Gelijns, Chair, Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier: NCT04371393 History of Changes
Other Study ID Numbers: GCO 08-1078-0014
First Posted: May 1, 2020 Key Record Dates
Last Update Posted: May 1, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All of the individual participant data collected during the trial, after deidentification.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Analytic Code
Time Frame: De-identified study data sets must be submitted to the designated NHLBI Program Official no later than 3 years after the end of the clinical activity (final patient follow-up, etc.) or 2 years after the main paper of the trial has been published, whichever comes first. Data are prepared by the study coordinating center and sent to the designated PO for review prior to release.
Access Criteria: Anyone who wishes to access the data.

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Expand
Thanks Dave sss.
This is what we have been waiting for. Seems many hear are more interested in the other camps than what is going on in our back yard.

A lot of very interesting information hear.
Not yet recruing, we are enrolling, the head line of the last announcement confirms. Previous reported as a phase 2-3 trial now phase 3. This must have changed after the FDA got the results of the 12 patients and is likely that this is why the trial went from 240 - 300
Primary Outcome Measures:
Number of all-cause mortality [ Time Frame: 30 days ]
Number of all-cause mortality within 30 days of randomization.
This is very important for us.
Success or --- f ( I shall not say it )

The study is designed to have three interim analyses for stopping accrual early for efficacy and futility when 30%, 45% and 60% of the 300 patients

The first look will be at 30% enrollment + 30 days , just 90 patients.

What will DMC need to take action ? To show that I am not ramping all the time, I will look at ---f first
Adverse events, this is always considered however they would need to be very serious in these settings . We know our safty record.
Looking at survival, 30% or 13 patients or above and they would take a closer look at it when we reach 45%.

Efficacy Match the previous results and this I believe will be triggered, why have a look if you haven't at least some intention to stop the trial. 37 survivors and the trial should be called. That could be in less than 6 weeks.

If the trial proceeds longer than say 2 months it would be a very strong indication that the interim results were short of magnificent however many trials return results
with only very marginal success and questionable safty and still are considered successful.

I am also very impressed with the depth of the secondary outcomes , unless the collection of data and testing is compromised in some way , the out come will be definite. No more trials for this application.

So much more to come in regards to ARDS in the next couple of weeks . The big ones CHF and CLBP are in range now , we have the potential of multi partnerships even with the US government.
All we need is good health for family and friends, stay safe and we will have a wonderful 6 months.
Good luck all.

	Arm	Intervention/treatment
1	Experimental: Remestemcel-L® Plus Standard of Care Intravenous infusion of remestemcel-L® 2x10^6 MSC/kg of body weight plus standard of care	Biological: Remestemcel-L® administered twice during the first week, with the second infusion at 4 days following the first injection (± 1 day)
2	Placebo Comparator: Placebo Plus Standard of Care Placebo (Plasma-Lyte) plus standard of care	Drug: Placebo administered twice during the first week, with second infusion at 4 days following the first injection (± 1 day)

(20min delay)
Last $1.01		Change 0.030(3.06%)		Mkt cap ! $1.153B

Open	High	Low	Value	Volume
$1.01	$1.04	99.0¢	$5.111M	5.050M

No.	Vol.	Price($)
1	48333	1.005
3	49000	1.000
3	80800	0.995
5	129515	0.990
1	3300	0.985

Price($)	Vol.	No.
1.020	136540	9
1.025	63000	3
1.030	28077	3
1.040	27850	2
1.045	103431	6

Thanks Dave sss.This is what we have been waiting for. Seems...

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

Emerald & Azure score Digger & Dealer awards

Bitcoin: Current State of Play & Where to Next | Swyftx

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

	ClinicalTrials.gov Identifier: NCT04371393
1	Recruitment Status: Not yet recruiting First Posted: May 1, 2020 Last Update Posted: May 1, 2020 SeeContacts and Locations

	Study Type:	Interventional (Clinical Trial)
1	EstimatedEnrollment:	300 participants
2	Allocation:	Randomized
3	Intervention Model:	Parallel Assignment
4	Intervention Model Description:	This will be a randomized (1:1 ratio), double blind, parallel design, placebo controlled trial.
5	Masking:	Triple (Participant, Investigator, Outcomes Assessor)
6	Masking Description:	This is a randomized clinical trial, in which the patients and investigators are masked to treatment assignment.
7	Primary Purpose:	Treatment
8	Official Title:	MesenchymalStem Cellsfor the Treatment of Moderate to SevereCOVID-19 Acute Respiratory Distress Syndrome
9	EstimatedStudy Start Date:	April 2020
10	EstimatedPrimary Completion Date:	April 2021
11	EstimatedStudy Completion Date:	April 2022

	Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
1	Sexes Eligible for Study:	All
2	Accepts Healthy Volunteers:	No

	Principal Investigator:	Annetine C Gelijns, PhD	Icahn School of Medicine at Mount Sinai
1	Study Director:	Michael Mack, MD	Baylor Research Institute
2	Study Director:	Peter Smith, MD	Duke University

Responsible Party:	Annetine Gelijns, Chair, Department of Population Health Science & Policy, Icahn School of Medicine at Mount Sinai
ClinicalTrials.gov Identifier:	NCT04371393 History of Changes
Other Study ID Numbers:	GCO 08-1078-0014
First Posted:	May 1, 2020 Key Record Dates
Last Update Posted:	May 1, 2020
Last Verified:	April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	Yes
Plan Description:	All of the individual participant data collected during the trial, after deidentification.
Supporting Materials:	Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) Clinical Study Report (CSR) Analytic Code
Time Frame:	De-identified study data sets must be submitted to the designated NHLBI Program Official no later than 3 years after the end of the clinical activity (final patient follow-up, etc.) or 2 years after the main paper of the trial has been published, whichever comes first. Data are prepared by the study coordinating center and sent to the designated PO for review prior to release.
Access Criteria:	Anyone who wishes to access the data.

Studies a U.S. FDA-regulated Drug Product:	Yes
Studies a U.S. FDA-regulated Device Product:	No

Thanks Dave sss.This is what we have been waiting for. Seems...

Top Stories

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

Emerald & Azure score Digger & Dealer awards

Bitcoin: Current State of Play & Where to Next | Swyftx

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News